Navigation Links
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
Date:2/17/2009

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- At the 5th World Health Organization Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Novavax, Inc. (Nasdaq: NVAX) announced favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to be important for protection against influenza disease. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain. This strain of avian influenza emerged in humans in Indonesia in 2005 and has caused 135 documented cases, 81% of which have been fatal. (1)

In this study, the vaccine demonstrated strong HAI antibody titers against the H5N1 A/Indonesia strain. The study evaluated individuals from 18 to 40 years of age who received two injections of 15 micrograms (mcg), 45 mcg, or 90 mcg of vaccine or a placebo. The HAI titers to the vaccine strain increased with increasing doses. In the 90 mcg group, 63.6% of subjects achieved a four-fold or greater rise in HAI titers when compared to baseline and titers of at least forty (i.e., greater than or equal to 1:40). All subjects tested negative for antibodies to the H5N1 A/Indonesia strain before vaccination and no responses were observed among individuals who received a placebo. Novavax's proprietary VLPs contain the surface proteins (hemagglutinin [HA] and neuraminidase [NA]) and matrix protein (M1) of the H5N1 A/Indonesia strain. Additional immunological responses induced by the other components of the vaccine are being evaluated, including respons
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
2. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
3. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
4. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
5. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
6. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
7. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Surgical Theater, LLC announced today the ... Advisory Board. New members include Ori J. ... Development and New Technologies for Given Imaging Ltd., ... Vice President and General Manager of Philips Healthcare,s ... simulation technology to brain surgery and has developed ...
(Date:7/28/2014)... July 28, 2014  Air Products (NYSE: ... medical oxygen is vital to any healthcare facility. This ... not only improve the efficiency of its oxygen supply ... highlight these systems—including systems for emergency oxygen supply ... August 4-5 at the 51 st ASHE ...
(Date:7/28/2014)... -- UBM Medica US announces that Diagnostic Imaging ... professionals, explored the complex situation regarding measuring the ... The shift from fee-for-service has left radiology at a ... determined in the new payment model . ... who recognized the complexity of the radiologist,s value: ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Diagnostic Imaging Delves into Measuring the Radiologist's Value 2
... Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") ... Intention to make a normal course issuer bid with ... TSX has accepted the Notice of Intention. Under the ... for cancellation, commencing August 25, 2011, 1,000,000 of its ...
... a leading provider of healthcare IT and medical billing solutions, ... 2011 Inc. 5000 list, a compendium of the most entrepreneurial ... the second year in a row that ITelagen qualified for ... position #2093, with an extraordinary four-year growth rate of 120.22%. ...
Cached Medicine Technology:Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 2Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 3ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies 2
(Date:7/28/2014)... --,The more chronic medical conditions people have at retirement ... new study claims. Since nearly four in ... Johns Hopkins Bloomberg School of Public Health in Baltimore ... life expectancy are slowing in the United States. ... disease and heart failure is now the norm and ...
(Date:7/28/2014)... 2014 (HealthDay News) -- Endurance runners are far more ... heart condition, according to a new study. ... events in warm climates are actually 10 times more ... the less common sudden death of a young and ... as an irregular heartbeat, often gets a lot more ...
(Date:7/28/2014)... Most cells do not divide unless there is enough ... cells and other cell types circumvent this rule. Researchers ... mechanism that overrides the cells, warning signals, enabling cancers ... supply. In the process, the researchers found that lysosomes ... cell division decisions. They also uncovered new evidence that ...
(Date:7/28/2014)... Washington, NY (PRWEB) July 28, 2014 Parker ... many years fighting to ensure that the heroes of 9/11 ... Fund (VCF) has announced an important deadline. According to a ... were diagnosed with a covered cancer on or before October ... October 12, 2014. First responders and others who were allegedly ...
(Date:7/28/2014)... July 28, 2014 The Brooke ... has donated more than 200,000 books to children and ... the launch of Brooke’s Cooks, a new initiative designed ... healthy living among at-risk children and their families in ... a series of nutrition information workshops, cooking demonstrations and ...
Breaking Medicine News(10 mins):Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Cell's recycling center implicated in division decisions 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... Rare Diseases, BETHESDA, Md., April 24 ... of Representatives for passing,legislation to reauthorize the Small ... testimony from Robert J. Beall, Ph.D., president and ... requiring that,special attention be given to research for ...
... The following are,excerpts from an article in The ... Republican National Committee:, Congressional Democrats are backing away ... saying that even if,their party controls the White House ... some senators, the promises made by Sens. Barack Obama ...
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... how brain cell communication may be altered in schizophrenia ... at the Medical College of Georgia, a 2008 Distinguished ... Alliance Eminent Scholar in Neuroscience and professor in the ... of 11 scientists to receive the award, which includes ...
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced that ... Administration (FDA) to market over-the-counter (OTC),Nicotine Polacrilex Gum USP, ... The FDA has determined the product to be ... mg (base) and 4 mg,(base), which is an aid ...
... April 24 Karen Ignagni,President and CEO ... issued,the following statement commending the Senate on ... Senate:, (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... the basis of their genetic,makeup. We applaud ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Lauds Congress for Passage of Small Business Innovation Research Program 2Health News:RNC: Dems Hedge on Healthcare 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 3Health News:Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum 2
... Conduit TCP is a synthetic porous ceramic ... similar to the mineral phase that comprises 70% ... that provides a scaffold that allows the attachment ... development of vascular networks within granules as well ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Weitlaner Beckmann retractor, sharp prongs, SS....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products: